Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Bio (NQ: CHRS )

4.980 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,585
Open 4.980
Bid (Size) 5.200 (1)
Ask (Size) 5.250 (2)
Prev. Close 4.980
Today's Range 4.980 - 4.980
52wk Range 3.600 - 14.03
Shares Outstanding 80,553,730
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
From Coherus BioSciences, Inc.
Via GlobeNewswire
Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2
Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics. 
Via Talk Markets

Performance

YTD
-41.48%
-41.48%
1 Month
-38.82%
-38.82%
3 Month
-26.44%
-26.44%
6 Month
-26.11%
-26.11%
1 Year
-34.21%
-34.21%

More News

Read More
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
Via Benzinga
Why Is AbbVie Stock Trading Down Today?
Via Benzinga
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
From Coherus BioSciences, Inc.
Via GlobeNewswire
Looking Into Coherus BioSciences's Return On Capital Employed
Via Benzinga
6 Analysts Have This to Say About Coherus BioSciences
Via Benzinga
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That Could Blast Off In May
Via Benzinga
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Prices Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Earnings Preview
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Vodafone, Calliditas Therapeutics, Rumble And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Coherus Announces Proposed Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Present at Upcoming Investor Conferences in May
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.